Navigation Links
ATCC Examined the Importance of High-quality Controls in Assay Design and Development During the Association for Molecular Pathology (AMP) 2013 Annual Meeting
Date:11/25/2013

Manassas, VA (PRWEB) November 25, 2013

The use of well-defined controls in assay development is essential for determining the reliability and reproducibility of data obtained from molecular applications. ATCC spoke out on this topic during its first participation at the Corporate Workshop Day at the AMP 2013 Annual Meeting, emphasizing the importance of using authenticated and highly characterized biomaterials for assay development and verification. More than 75 researchers from pharmaceutical and molecular diagnostics companies attended the workshop. The presentation was divided into two parts, first focusing on controls for genetic mutations in cancer biology, followed by a discussion on the detailed characterization of ATCC infectious disease strains and nucleic acid controls.

Fang Tian, Ph.D., Lead Scientist for ATCC Cell Systems, led the discussion by describing the rapidly changing landscape of diagnostics, including the vast amount of human genetic data currently available via open-access. Moreover, with the development of smaller, faster, and more affordable sequencing technologies, investigators now require a stable and renewable source of controls, such as fully characterized and authenticated cell lines. To meet these needs, ATCC organized Tumor Cell Panels representing cell lines grouped by tissue type and annotated with published gene mutation data. Further, Dr. Tian explained, “ATCC is not only pairing cell lines with published gene mutation data, we are also performing extensive laboratory analyses to confirm the presence, stability, and expression of genetic mutations using tools like sequencing, PCR, and Western Blot.”

Liz Kerrigan, Director of Standards at ATCC noted, “There are a lot of choices for controls in research, but it’s imperative to obtain controls from a reliable source; knowing how they were produced and how identities were verified – that’s the importance of authentication.” ATCC maintains a rigorous quality control program under ISO/IEC 17025, ensuring the identity and purity of biological materials. Cultures housed within the ATCC repository are managed under a seed stock banking concept, which limits passage and allows for strict quality control testing to be performed on both seed and distribution materials. In addition to providing supplementary testing for tumor cell lines, ATCC also performs extensive analyses on geographically diverse infectious disease isolates to determine serotype, toxinotype, and multidrug-resistance (MDR) profiles.

As the tools available to laboratories change, ATCC is adapting to make it easier for investigators to locate genetic and phenotypic data related to the controls they need to challenge assay design and verify results. ATCC offers a growing list of Tumor Cell Panels, Genetic Alteration Panels, infectious disease and multidrug-resistant strains, synthetic and native nucleic acids, and Certified Reference Materials (CRM) – including the newest KRAS-mutation CRMs – for assay development, inclusivity/exclusivity testing, and Limits of Detection (LOD).

Interviews with the speakers and the workshop presentation can be made available. Additional information about the extensive portfolio of ATCC cells and microbiological materials can be found at http://www.atcc.org.

About the Speakers
Liz Kerrigan
Liz Kerrigan is the Director of Standards at ATCC in Manassas, Virginia. Liz serves as the ATCC representative to the United States Pharmacopeial (USP) Convention, ANSI (American National Standards Institute), CLSI (Clinical Laboratory Standards Institute), and the AOAC/DHS SPADA (Stakeholder Panel on Agent Detection Assays). She is a member of PDA, ASM, USP, ISBER and AMP.

Fang Tian, Ph.D.
Dr. Fang Tian is the Lead Scientist for ATCC Cell Systems with extensive experience in cell biology and molecular biology. She has a strong interest in developing cell lines and cell line panels, focusing on molecular pathologies, cell signaling pathways, and genetic alterations. Dr. Tian was a Research Fellow at the Massachusetts General Hospital, Harvard Medical School. She conducted her postdoctoral research at the Hillman Cancer Institute, University of Pittsburgh Medical Center.

About ATCC
ATCC serves and supports the scientific community with industry-standard products and innovative solutions. With the world’s largest and most diverse collection of human, animal and plant cell lines, molecular genomic tools, microorganisms and biological products, ATCC is a trusted biological resource for the worldwide research community. Together, the people of ATCC share in its mission to acquire, authenticate, preserve, develop, and distribute biological materials and information for the advancement of scientific knowledge. ATCC is a non-profit organization with headquarters in Manassas, VA.

Read the full story at http://www.prweb.com/releases/2013/11/prweb11365669.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Alternatives to Medicares fee-for-service payment system examined
2. Implant Overdentures - Dr. Jonathan Penchas Has Examined Studies That Show a High Success Rate and Advantages over Long Period
3. Ultrasound Systems Market Examined by GBI Research in New Insightful Report Now Available at MarketPublishers.com
4. Age Old Problem is Examined in New Book
5. Black American Obesity Examined In The Latest FinancesOnline.com Article
6. US POCT Market Examined & Forecast by VPG in New In-Demand Report Available at MarketPublishers.com
7. Colon Cleanse for Adults Over 40 Years of Age Now Examined Online at eHealthMax.com
8. Internal Hemorrhoids At-Home Treatments for Adults Over 40 Now Examined Online by eHealthMax.com
9. Natural Ways to Lower Cholesterol Now Examined for Adults Over 40 at eHealthMax.com
10. North American Drug Delivery Systems Market Examined by MarketsandMarkets in Topical Study Available at MarketPublishers.com
11. Eye Lash Extension Products Now Examined for Ladies at eHealthMax.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... TX (PRWEB) , ... December 07, 2016 , ... ... 2016 Top 20 Marketing Campaign Winner in the Folio: Marketing Awards competition. Live ... recognize the year’s best in pioneering, inventive, and ultimately successful projects undertaken by ...
(Date:12/7/2016)... Scottsdale, AZ (PRWEB) , ... ... ... pioneer, ElectroMedical Technologies, announced its newest portable bioelectronic medicine device WellnessPro Plus ... , WellnessPro Plus substantially enhances the WellnessPro platform by expanding the treatment ...
(Date:12/7/2016)... ... 2016 , ... “Walking With God: Inspirational Lessons from My Life's Journey”: ... be aware of God's direction in their lives. “Walking With God: Inspirational Lessons from ... active church leader. , Sanford says, “I enjoy sharing the true stories ...
(Date:12/7/2016)... ... December 07, 2016 , ... Dr. Greg Leyer, the ... Probiotic Association’s Washington DC workshop on November 2nd. The conference was an opportunity ... probiotic dietary supplement regulations. , Dr. Leyer spoke about two main topics ...
(Date:12/6/2016)... ... 2016 , ... The International Vaccine Institute (IVI) and GeneOne ... Middle East Respiratory Syndrome Coronavirus (MERS-CoV). The collaboration will accelerate MERS-CoV vaccine development ... in the event of a future outbreak. , IVI and GeneOne held a ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... --  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ... the ralinepag phase 2 trial.  Ralinepag is an oral, ... the treatment of pulmonary arterial hypertension (PAH). The study ... "This marks an important step in the development of ... our pipeline," said Amit Munshi , Arena,s President ...
(Date:12/7/2016)... , Dec. 7, 2016   TraceLink Inc ... for connecting the Life Sciences supply chain and ... today announced that Tjoapack has selected TraceLink,s serialization ... customers comply with the rapidly approaching serialization deadlines ... (DSCSA) in 2017 and the EU Falsified Medicines ...
(Date:12/7/2016)... ZIONA SCIENCE PARK , ... biotechnology company Kadimastem (TASE: KDST) announced today the signing of a ... collaboration between the companies. The synergy between the companies will assist ... collaboration as a worldwide leader in innovative treatment for severe diseases ... ...
Breaking Medicine Technology: